Salix Pharmaceuticals, Ltd. Stock

Stocks

17/03/15	Endo : Valeant trumps Endo with $10.96 billion bid for Salix Pharma	RE
17/03/15	Bank of Montreal : TSX climbs on upbeat sentiment ahead of Fed meeting	RE
17/03/15	Wall St. bounces as dollar drops, Fed worries ease	RE
16/03/15	Endo : withdraws offer for Salix	RE
12/03/15	Valeant Pharmaceuticals Intl : TSX rebounds as energy shares advance with oil price	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
05/03/15	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
24/02/15	Shire : buys Meritage Pharma for at least $70 million	RE
24/02/15	Canadian Natural Resources : TSX gains on Valeant news; financial stocks weigh	RE
24/02/15	Boeing : Nasdaq ends up 9th session; S&P 500, Dow dip with energy	RE
23/02/15	BioMarin Pharmaceutical : Exclusive - Rare disease drugmaker PTC Therapeutics explores sale: sources	RE
22/02/15	Salix Pharmaceuticals : Valeant nears deal to buy Salix for about $10 billion - WSJ	RE

11/03/15	Salix Pharmaceuticals : Confirms Receipt of an Unsolicited Proposal from Endo International plc	BU
03/03/15	Salix Pharmaceuticals : Reports 4Q2014 and FY2014 Results	BU
28/02/15	Salix Pharmaceuticals : SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Salix Pharmaceuticals, Ltd. And Encourages Investors To Contact The Firm For Additional Information	BU
27/02/15	Salix Pharmaceuticals : Stockholders Encouraged to Contact Securities Law Firm about Takeover	PR
27/02/15	SALIX PHARMACEUTICALS : SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout	BU

01/04/15	Valeant Pharmaceuticals Intl : Le laboratoire canadien Valeant conclut l'acquisition de Salix
30/03/15	Sanofi ne juge pas des acquisitions "indispensables"-Pdt
17/03/15	Le recul du dollar a favorisé le rebond de Wall Street
16/03/15	Allergan : Valeant relève son offre sur Salix, Endo jette l'éponge
16/03/15	BlackBerry : Les valeurs à suivre sur les marchés américains

Manager	Title	Age	Since
Josh Coyle SAM	Sales & Marketing	-	01/01/2018
John Temperato SAM	Sales & Marketing	61	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SALIX PHARMACEUTICALS, LTD.	-.--%	+0.16%	-	-	0
MERCK & CO., INC.	+0.96%	+3.12%	+56.19%	+15.47%	315B
MERCK KGAA	+0.04%	-1.16%	+21.42%	-13.46%	67.93B
HALOZYME THERAPEUTICS, INC.	-0.99%	+2.64%	+35.25%	+81.44%	9.23B
KYOWA KIRIN CO., LTD.	-1.26%	-1.95%	+2.83%	-4.98%	8.43B
SK BIOPHARMACEUTICALS CO., LTD.	-1.03%	-1.79%	-24.11%	-10.07%	4.07B
BETTA PHARMACEUTICALS CO., LTD.	+0.38%	-9.58%	-5.58%	+22.13%	3.77B
YUHAN CORPORATION	+0.86%	+1.01%	-43.84%	+10.01%	3.54B
SUPERNUS PHARMACEUTICALS, INC.	-1.94%	-1.66%	+43.68%	+53.35%	2.72B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-2.81%	-6.33%	+5.13%	-9.94%	2.13B
Average	-0.59%	-0.91%	+10.11%	+16.00%	46.3B
Weighted average by Cap.	+0.65%	+3.04%	+46.44%	+11.69%

Employees

Sector